

Poster presentation

Public Policy and Aids Vaccine Development and Trials

Matthew Okai*‡ and Jocelyn Abban

Address: Nellis Aids Foundation, P.O.Box DK681, Darkuman-Accra, Ghana

Email: Matthew Okai* - nellisaids@mail.com

* Corresponding author ‡Presenting author

from 2005 International Meeting of The Institute of Human Virology
Baltimore, USA, 29 August – 2 September 2005

Published: 8 December 2005

Retrovirology 2005, **2**(Suppl 1):P72 doi:10.1186/1742-4690-2-S1-P72

Background

Several policy and economic challenges come up in the quest for Aids Vaccine development and trial in Ghana and Africa as a whole. In resource limited countries like Ghana, individuals often must wait for several years before they have access to licensed vaccines. Key policy issues and economic challenges affecting Aids vaccine development and trial include; providing adequate funding for public and private sector research, enforcing protection for human subjects in clinical trials as well as speeding regulatory consideration of clinical trials.

Method

This presentation will look at potential policy interventions and each stage of the product development and delivery process. There will be a review of academic writings and current policy proposals and well as considering the merits and limitations of several proposals.

Results

As far as Aids vaccine research is concern, Policy makers have a critical role to play. A variety of policy interventions are required to achieve accelerated results.

Conclusion

For speedy Aids vaccine research and trials, policy makers should carefully access the merits of policy proposals and enact changes as and when it's necessary.